{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T07:11:57Z","timestamp":1778483517968,"version":"3.51.4"},"reference-count":133,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.critrevonc.2026.105269","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T16:35:41Z","timestamp":1773419741000},"page":"105269","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The versatility of SIRP\u03b1: Novel perspectives on tumor microenvironment regulation and targeted therapy beyond the CD47-SIRP\u03b1 axis"],"prefix":"10.1016","volume":"222","author":[{"given":"Yongqi","family":"Kang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengying","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shukai","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chongyang","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105269_bib1","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1158\/2159-8290.CD-20-1638","article-title":"Overcoming resistance to tumor-targeted and immune-targeted therapies","volume":"11","author":"Aldea","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105269_bib2","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.111260","article-title":"Macrophages require Skap2 and Sirp\u03b1 for integrin-stimulated cytoskeletal rearrangement","author":"Alenghat","year":"2012","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.critrevonc.2026.105269_bib3","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1158\/1078-0432.CCR-20-3706","article-title":"Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies","volume":"27","author":"Ansell","year":"2021","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105269_bib4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.critrevonc.2026.105269_bib5","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1038\/s41467-021-23442-z","article-title":"Intratumoral SIRP\u03b1-deficient macrophages activate tumor antigen-specific cytotoxic T cells under radiotherapy","volume":"12","author":"Bian","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105269_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1679271","article-title":"Emerging macrophage-based therapies for cancer: a review of preclinical and clinical advances","volume":"16","author":"Brancewicz","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105269_bib7","article-title":"CV1-secreting sCAR-T cells potentiate the abscopal effect of microwave ablation in heterogeneous tumors","volume":"6","author":"Cao","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.critrevonc.2026.105269_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/9435030","article-title":"CD47-SIRP \u03b1 axis as a biomarker and therapeutic target in cancer: current perspectives and future challenges in nonsmall cell lung cancer","volume":"2020","author":"Catal\u00e1n","year":"2020","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.critrevonc.2026.105269_bib9","first-page":"97","article-title":"DSP107 combines inhibition of CD47\/SIRP\u03b1 axis with activation of 4-1BB to trigger anticancer immunity","volume":"41","author":"Cendrowicz","year":"2022","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"10.1016\/j.critrevonc.2026.105269_bib10","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1158\/2767-9764.CRC-23-0634","article-title":"Discovery and preclinical activity of bms-986351, an antibody to SIRP\u03b1 that enhances macrophage-mediated tumor phagocytosis when combined with opsonizing antibodies","volume":"4","author":"Chan","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.critrevonc.2026.105269_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpha.2024.101099","article-title":"Therapeutic strategies targeting CD47-SIRP\u03b1 signaling pathway in gastrointestinal cancers treatment","volume":"15","author":"Che","year":"2025","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.critrevonc.2026.105269_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003737","article-title":"Delivery of CD47 blocker SIRP\u03b1-Fc by CAR-T cells enhances antitumor efficacy","volume":"10","author":"Chen","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105269_bib13","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s40164-024-00587-3","article-title":"Identification of a novel subtype of SPP1 + macrophages expressing SIRP\u03b1: implications for tumor immune evasion and treatment response prediction","volume":"13","author":"Chen","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105269_bib14","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","article-title":"Macrophages in immunoregulation and therapeutics","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.critrevonc.2026.105269_bib15","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/cac2.12345","article-title":"Tumor-associated macrophages in liver cancer: From mechanisms to therapy","volume":"42","author":"Cheng","year":"2022","journal-title":"Cancer Commun. Lond. Engl."},{"key":"10.1016\/j.critrevonc.2026.105269_bib16","article-title":"Oncolytic virus M1 functions as a bifunctional checkpoint inhibitor to enhance the antitumor activity of DC vaccine","volume":"4","author":"Dan","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.critrevonc.2026.105269_bib17","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1158\/1078-0432.CCR-25-0229","article-title":"Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib\/II Study and Correlative Analysis","volume":"31","author":"Daver","year":"2025","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105269_bib18","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1182\/blood.2024027506","article-title":"The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy","volume":"146","author":"Daver","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105269_bib19","doi-asserted-by":"crossref","first-page":"8162","DOI":"10.1007\/s12035-016-0302-8","article-title":"SIRP Alpha Protein Downregulates in Human Astrocytoma: Presumptive Involvement of Hsa-miR-520d-5p and Hsa-miR-520d-3p","volume":"54","author":"Deshpande","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.critrevonc.2026.105269_bib20","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200839","article-title":"The SIRP\u03b1\u2013CD47 immune checkpoint in NK cells","volume":"218","author":"Deuse","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.critrevonc.2026.105269_bib21","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11523-025-01130-y","article-title":"A Phase 1b\/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors","volume":"20","author":"Eng","year":"2025","journal-title":"Target. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105269_bib22","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41568-019-0183-z","article-title":"Phagocytosis checkpoints as new targets for cancer immunotherapy","volume":"19","author":"Feng","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105269_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.570963","article-title":"SIRPa on Mouse B1 Cells Restricts Lymphoid Tissue Migration and Natural Antibody Production","volume":"11","author":"Franke","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105269_bib24","article-title":"Shaping Polarization Of Tumor-Associated Macrophages In Cancer Immunotherapy","volume":"13","author":"Gao","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105269_bib25","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.1172\/JCI135528","article-title":"Selective SIRP\u03b1 blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistance","volume":"130","author":"Gauttier","year":"2020","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.critrevonc.2026.105269_bib26","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s12951-024-02622-1","article-title":"Engineering nanoparticles-enabled tumor-associated macrophages repolarization and phagocytosis restoration for enhanced cancer immunotherapy","volume":"22","author":"Gong","year":"2024","journal-title":"J. Nanobiotechnology"},{"key":"10.1016\/j.critrevonc.2026.105269_bib27","doi-asserted-by":"crossref","first-page":"5392","DOI":"10.1021\/acsnano.4c13463","article-title":"Rationally Engineered Bispecific Nanoimmunoblocker Restores Anticancer Immunity via Dual Immune Checkpoint Blockade","volume":"19","author":"Guan","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.critrevonc.2026.105269_bib28","article-title":"Reversing immune suppression and potentiating photothermal immunotherapy via bispecific immune checkpoint inhibitor loaded hollow polydopamine nanospheres","author":"Guo","year":"2023","journal-title":"ACS Appl. Mater. Interfaces 15 1387913891."},{"key":"10.1016\/j.critrevonc.2026.105269_bib29","doi-asserted-by":"crossref","first-page":"13575","DOI":"10.2147\/JIR.S530775","article-title":"Sirp-\u03b1 Antibody Inhibits Renal Cell Carcinoma Progression via Akt1\/Akt2 Modulation in Tumor-Associated Macrophages","volume":"18","author":"Hao","year":"2025","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.critrevonc.2026.105269_bib30","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s13402-019-00469-5","article-title":"CD47: role in the immune system and application to cancer therapy","volume":"43","author":"Hayat","year":"2020","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105269_bib31","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint signaling and cancer immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.critrevonc.2026.105269_bib32","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1007\/s11427-022-2285-6","article-title":"Design of a novel chimeric peptide via dual blockade of CD47\/SIRP\u03b1 and PD-1\/PD-L1 for cancer immunotherapy","volume":"66","author":"Hu","year":"2023","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.critrevonc.2026.105269_bib33","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/s43018-023-00691-z","article-title":"Sirp\u03b1 on tumor-associated myeloid cells restrains antitumor immunity in colorectal cancer independent of its interaction with CD47","volume":"5","author":"Huang","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105269_bib34","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41419-025-07779-7","article-title":"SIRP\u03b1 blockade therapy potentiates immunotherapy by inhibiting PD-L1+ myeloid cells in hepatocellular carcinoma","volume":"16","author":"Huang","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.critrevonc.2026.105269_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052143","article-title":"Engagement of SIRP\u03b1 Inhibits Growth and Induces Programmed Cell Death in Acute Myeloid Leukemia Cells","volume":"8","author":"Irandoust","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.critrevonc.2026.105269_bib36","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.cell.2018.09.006","article-title":"A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade","volume":"175","author":"Jerby-Arnon","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105269_bib37","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41420-023-01472-4","article-title":"SIRP\u03b1 blockade improves the antitumor immunity of radiotherapy in colorectal cancer","volume":"9","author":"Ji","year":"2023","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.critrevonc.2026.105269_bib38","first-page":"248","article-title":"Engineered macrophage nanoparticles enhance microwave ablation efficacy in osteosarcoma via targeting the CD47-SIRP\u03b1 Axis: A novel Biomimetic immunotherapeutic approach","volume":"47","author":"Ji","year":"2025","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.critrevonc.2026.105269_bib39","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.7150\/ijbs.60782","article-title":"CD47\/SIRP\u03b1 pathway mediates cancer immune escape and immunotherapy","volume":"17","author":"Jia","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105269_bib40","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12964-024-01555-4","article-title":"Discovery of a novel small molecule as CD47\/SIRP\u03b1 and PD-1\/PD-L1 dual inhibitor for cancer immunotherapy","volume":"22","author":"Jin","year":"2024","journal-title":"Cell Commun. Signal. CCS"},{"key":"10.1016\/j.critrevonc.2026.105269_bib41","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1182\/bloodadvances.2018030577","article-title":"Targeting CD47 in S\u00e9zary syndrome with SIRP\u03b1Fc","volume":"3","author":"Johnson","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2026.105269_bib42","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2024.286208","article-title":"Evorpacept plus rituximab for the treatment of relapsed or refractory non-Hodgkin lymphoma: results from the phase I ASPEN-01 study","author":"Kim","year":"2025","journal-title":"Haematologica 110 21022112"},{"key":"10.1016\/j.critrevonc.2026.105269_bib43","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.tips.2024.04.006","article-title":"Immune checkpoint blockade resistance in lung cancer: emerging mechanisms and therapeutic opportunities","volume":"45","author":"Konen","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105269_bib44","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1038\/s41598-024-85065-w","article-title":"PD-L1 monoclonal antibody alleviated MI injury of left ventricular function via modulating CD47\/SHP2\/SIRP\u03b1\/SYK\/Fc\u03b3R signalings in tumor associated macrophages","volume":"15","author":"Kong","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105269_bib45","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/S1470-2045(21)00584-2","article-title":"Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study","volume":"22","author":"Lakhani","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105269_bib46","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010565","article-title":"First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer","volume":"13","author":"Lakhani","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105269_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102550","article-title":"Nanoparticle-formulated mRNA encoding engineered multivalent SIRP\u03b1-Fc fusion proteins shows robust anti-cancer activity in preclinical models","volume":"36","author":"Lal","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.critrevonc.2026.105269_bib48","doi-asserted-by":"crossref","first-page":"22298","DOI":"10.1021\/acsnano.4c06471","article-title":"Dual-Action Protein-siRNA Conjugates for Targeted Disruption of CD47-Signal Regulatory Protein \u03b1 Axis in Cancer Therapy","volume":"18","author":"Lee","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.critrevonc.2026.105269_bib49","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1186\/s12951-024-02883-w","article-title":"Ultrasound-responsive nanocarriers with siRNA and Fe3O4 regulate macrophage polarization and phagocytosis for augmented non-small cell lung cancer immunotherapy","volume":"22","author":"Li","year":"2024","journal-title":"J. Nanobiotechnology"},{"key":"10.1016\/j.critrevonc.2026.105269_bib50","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2024.286923","article-title":"An oncolytic vaccinia virus expressing anti-CD47 nanobody exerts enhanced antitumor activity by mediating innate and adaptive immune cell infiltration and activation in the lymphoma tumor microenvironment","author":"Li","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2026.105269_bib51","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.jconrel.2024.12.059","article-title":"Microglia membrane-mediated trans-blood-brain barrier prodrug micelles enhance phagocytosis for glioblastoma chemo-immunotherapy","volume":"378","author":"Li","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.critrevonc.2026.105269_bib52","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jconrel.2024.07.039","article-title":"A polymeric nanoplatform enhances the cGAS-STING pathway in macrophages to potentiate phagocytosis for cancer immunotherapy","volume":"373","author":"Li","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.critrevonc.2026.105269_bib53","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00262-025-04025-z","article-title":"SIRP\u03b1 + CD209 + cell: a specialized antigen-presenting cell that contributes to anti-SIRP\u03b1\/RT therapy in colorectal cancer","volume":"74","author":"Li","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2026.105269_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119150","article-title":"The role of CD47-SIRP\u03b1 immune checkpoint in tumor immune evasion and innate immunotherapy","volume":"273","author":"Li","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.critrevonc.2026.105269_bib55","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1183850","article-title":"Inhibition of SIRP\u03b1 in dendritic cells potentiates potent antitumor immunity","volume":"5","author":"Liu","year":"2016","journal-title":"OncoImmunology"},{"key":"10.1016\/j.critrevonc.2026.105269_bib56","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.jare.2024.12.043","article-title":"Targeting macrophages in cancer immunotherapy: Frontiers and challenges","volume":"76","author":"Liu","year":"2025","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.critrevonc.2026.105269_bib57","article-title":"Concurrent immune checkpoint blockade for enhanced cancer immunotherapy utilizing engineered hybrid nanovesicles","volume":"15","author":"Liu","year":"2024","journal-title":"Front. Pharm."},{"key":"10.1016\/j.critrevonc.2026.105269_bib58","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.immuni.2020.04.011","article-title":"The CD47-SIRP\u03b1 Immune Checkpoint","volume":"52","author":"Logtenberg","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.critrevonc.2026.105269_bib59","doi-asserted-by":"crossref","first-page":"31113","DOI":"10.1074\/jbc.M115.682914","article-title":"Cleavage of Signal Regulatory Protein \u03b1 (SIRP\u03b1) Enhances Inflammatory Signaling","volume":"290","author":"Londino","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.critrevonc.2026.105269_bib60","doi-asserted-by":"crossref","first-page":"37641","DOI":"10.1021\/jacs.5c12775","article-title":"Genetically Engineered Biomimetic Nanoparticles for Synergistic Activation of Glioma-Associated Macrophages against Glioblastoma","volume":"147","author":"Luo","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.critrevonc.2026.105269_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177271","article-title":"Dual checkpoint inhibition in M2 macrophages via anti-PD-L1 and siRNA-Loaded M1-Exosomes: Enhancing tumor immunity through RNA-targeting Strategies","volume":"990","author":"Mahmoudi","year":"2025","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.critrevonc.2026.105269_bib62","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","article-title":"Macrophages as tools and targets in cancer therapy","volume":"21","author":"Mantovani","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.critrevonc.2026.105269_bib63","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/imr.12527","article-title":"The CD47-SIRP\u03b1 signaling axis as an innate immune checkpoint in cancer","volume":"276","author":"Matlung","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.critrevonc.2026.105269_bib64","doi-asserted-by":"crossref","first-page":"5855","DOI":"10.1182\/bloodadvances.2024013277","article-title":"Magrolimab plus rituximab in relapsed\/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1\/2 trial","volume":"8","author":"Mehta","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2026.105269_bib65","doi-asserted-by":"crossref","first-page":"26320","DOI":"10.1002\/anie.202108342","article-title":"Genetically programmable fusion cellular vesicles for cancer immunotherapy","volume":"60","author":"Meng","year":"2021","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.critrevonc.2026.105269_bib66","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202410340","article-title":"Engineered nanoparticles for enhanced antitumoral synergy between macrophages and T cells in the tumor microenvironment","volume":"36","author":"Moon","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.critrevonc.2026.105269_bib67","first-page":"266","article-title":"A pan-allelic human SIRP\u03b1-blocking antibody, ES004-B5, promotes tumor killing by enhancing macrophage phagocytosis and subsequently inducing an effective T-cell response","volume":"7","author":"Niu","year":"2024","journal-title":"Antib. Ther."},{"key":"10.1016\/j.critrevonc.2026.105269_bib68","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T cell-based immunotherapy","volume":"16","author":"O\u2019Donnell","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105269_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.103939","article-title":"Is the new angel better than the old devil? Challenges and opportunities in CD47- SIRP\u03b1-based cancer therapy","volume":"184","author":"Olaoba","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2026.105269_bib70","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13045-020-00862-w","article-title":"Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy","volume":"13","author":"Pan","year":"2020","journal-title":"J. Hematol. Oncol. J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105269_bib71","article-title":"Role of signal regulatory protein \u03b1 in arsenic trioxide-induced promyelocytic leukemia cell apoptosis","volume":"6","author":"Pan","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105269_bib72","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13361","article-title":"Lack of SIRP -alpha reduces lung cancer growth in mice by promoting anti-tumour ability of macrophages and neutrophils","volume":"56","author":"Pan","year":"2023","journal-title":"Cell Prolif."},{"key":"10.1016\/j.critrevonc.2026.105269_bib73","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/eji.201243031","article-title":"Signal regulatory protein \u03b1 negatively regulates mast-cell activation following Fc\u03b5RI aggregation","volume":"43","author":"Pan","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105269_bib74","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/hep.26391","article-title":"Signal regulatory protein \u03b1 is associated with tumor-polarized macrophages phenotype switch and plays a pivotal role in tumor progression","volume":"58","author":"Pan","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.critrevonc.2026.105269_bib75","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1200\/JCO.21.01845","article-title":"Managing resistance to immune checkpoint inhibitors in lung cancer: treatment and novel strategies","volume":"40","author":"Passaro","year":"2022","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105269_bib76","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","article-title":"CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors","volume":"21","author":"Peng","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105269_bib77","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40364-022-00373-5","article-title":"Targeting CD47\/SIRP\u03b1 as a therapeutic strategy, where we are and where we are headed","volume":"10","author":"Qu","year":"2022","journal-title":"Biomark. Res."},{"key":"10.1016\/j.critrevonc.2026.105269_bib78","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s00262-025-04032-0","article-title":"Targeted CD47 checkpoint blockade using a mesothelin-directed antibody construct for enhanced solid tumor-specific immunotherapy","volume":"74","author":"Reischer","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2026.105269_bib79","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma","volume":"175","author":"Sade-Feldman","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105269_bib80","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.22.01794","article-title":"Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study","volume":"41","author":"Sallman","year":"2023","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105269_bib81","doi-asserted-by":"crossref","first-page":"11272","DOI":"10.1039\/D4SC00851K","article-title":"Macrophage-engaging peptidic bispecific antibodies (pBsAbs) for immunotherapy via a facile bioconjugation strategy","volume":"15","author":"Shao","year":"2024","journal-title":"Chem. Sci."},{"key":"10.1016\/j.critrevonc.2026.105269_bib82","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1158\/0008-5472.CAN-23-2875","article-title":"Lipid-Encapsulated mRNAs Encoding Complex Fusion Proteins Potentiate Antitumor Immune Responses","volume":"84","author":"Shuptrine","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105269_bib83","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1007\/s12672-025-03312-6","article-title":"Targeting the CD47-SIRPalpha checkpoint in multiple myeloma","volume":"16","author":"Sim","year":"2025","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105269_bib84","doi-asserted-by":"crossref","DOI":"10.1177\/00220345241305590","article-title":"Tumor-Intrinsic SIRPA Drives Pyroptosis Evasion in Head and Neck Cancer","author":"Song","year":"2025","journal-title":"J. Dent. Res."},{"key":"10.1016\/j.critrevonc.2026.105269_bib85","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1159\/000357820","article-title":"Signal regulatory protein alpha is present in several neutrophil granule populations and is rapidly mobilized to the cell surface to negatively fine-tune neutrophil accumulation in inflammation","volume":"6","author":"Stenberg","year":"2014","journal-title":"J. Innate Immun."},{"key":"10.1016\/j.critrevonc.2026.105269_bib86","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1189\/jlb.1110637","article-title":"Neutrophil apoptosis is associated with loss of signal regulatory protein alpha (SIRP\u03b1) from the cell surface","volume":"93","author":"Stenberg","year":"2012","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.critrevonc.2026.105269_bib87","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1158\/1078-0432.CCR-25-1826","article-title":"A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma","volume":"31","author":"Strati","year":"2025","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105269_bib88","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0304985","article-title":"Blockade of SIRP\u03b1-CD47 axis by anti-SIRP\u03b1 antibody enhances anti-tumor activity of DXd antibody-drug conjugates","volume":"19","author":"Sue","year":"2024","journal-title":"PLOS ONE"},{"key":"10.1016\/j.critrevonc.2026.105269_bib89","doi-asserted-by":"crossref","first-page":"30332","DOI":"10.1021\/acsnano.4c07364","article-title":"Engineered outer membrane vesicles as nanosized immune cell engagers for enhanced solid tumor immunotherapy","volume":"18","author":"Sun","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.critrevonc.2026.105269_bib90","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.trecan.2019.05.010","article-title":"Integrative approaches to cancer immunotherapy","volume":"5","author":"Szeto","year":"2019","journal-title":"Trends Cancer"},{"key":"10.1016\/j.critrevonc.2026.105269_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.123311","article-title":"Enhancing the anti-tumor activity and reprogramming M2 macrophages by delivering siRNAs against SIRP\u03b1 and STAT6 via M1 exosomes and combining with anti-PD-L1","volume":"361","author":"Taghavi-Farahabadi","year":"2025","journal-title":"Life Sci."},{"key":"10.1016\/j.critrevonc.2026.105269_bib92","article-title":"Cancer immunotherapy: Pros, cons and beyond","volume":"124","author":"Tan","year":"2020","journal-title":"Biomed. Pharm. Biomedecine Pharm."},{"key":"10.1016\/j.critrevonc.2026.105269_bib93","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s10147-024-02666-1","article-title":"The clinical significance of signal regulatory protein alpha expression in the immune environment of gastric cancer","volume":"30","author":"Tanaka","year":"2025","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105269_bib94","article-title":"Anticancer immune responses are hindered by cis interaction of inhibitory checkpoint SIRP\u03b1","author":"Tang","year":"2025","journal-title":"C. E N. C. E M M U N. O O G"},{"key":"10.1016\/j.critrevonc.2026.105269_bib95","article-title":"Expression of Signal Regulatory Protein Alpha in Tumor Cells is the Key Factor in Intrahepatic Cholangiocarcinoma","author":"Toshida","year":"2025","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105269_bib96","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006567","article-title":"BYON4228 is a pan-allelic antagonistic SIRP\u03b1 antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRP\u03b3 on T cells","volume":"11","author":"van Helden","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105269_bib97","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.celrep.2012.08.027","article-title":"SIRP\u03b1 Controls the Activity of the Phagocyte NADPH Oxidase by Restricting the Expression of gp91phox","volume":"2","author":"van Beek","year":"2012","journal-title":"Cell Rep."},{"key":"10.1016\/j.critrevonc.2026.105269_bib98","article-title":"Targeting phagocytosis checkpoints for cancer immunotherapy","author":"Veillette","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105269_bib99","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13045-025-01742-x","article-title":"HCB101: a novel potent ligand-trap Fc-fusion protein targeting the CD47-SIRP\u03b1 pathway with high safety and preclinical efficacy for hematological and solid tumors","volume":"18","author":"Wang","year":"2025","journal-title":"J. Hematol. Oncol. J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105269_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216412","article-title":"SIRPA enhances osteosarcoma metastasis by stabilizing SP1 and promoting SLC7A3-mediated arginine uptake","volume":"576","author":"Wang","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2026.105269_bib101","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1021\/acs.nanolett.4c00003","article-title":"Intracellular Magnetic Hyperthermia Enables Concurrent Down-Regulation of CD47 and SIRP\u03b1 To Potentiate Antitumor Immunity","volume":"24","author":"Wang","year":"2024","journal-title":"Nano Lett."},{"key":"10.1016\/j.critrevonc.2026.105269_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.123037","article-title":"situ production and precise release of bioactive GM-CSF and siRNA by engineered bacteria for macrophage reprogramming in cancer immunotherapy","volume":"317","author":"Wang","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.critrevonc.2026.105269_bib103","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00262-020-02679-5","article-title":"Tumor-selective blockade of CD47 signaling with a CD47\/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity","volume":"70","author":"Wang","year":"2021","journal-title":"Cancer Immunol. Immunother. CII"},{"key":"10.1016\/j.critrevonc.2026.105269_bib104","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1021\/acs.molpharmaceut.2c00073","article-title":"Recent Advances of Tumor Therapy Based on the CD47-SIRP\u03b1 Axis","volume":"19","author":"Wang","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.critrevonc.2026.105269_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113593","article-title":"MicroRNA-induced reprogramming of tumor-associated macrophages for modulation of tumor immune microenvironment","volume":"381","author":"Wu","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.critrevonc.2026.105269_bib106","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1658795","article-title":"Progress in targeting tumor-associated macrophages in cancer immunotherapy","volume":"16","author":"Xia","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105269_bib107","article-title":"Engineering Macrophages for Cancer Immunotherapy and Drug Delivery","volume":"32","author":"Xia","year":"2020","journal-title":"Adv. Mater. Deerfield Beach Fla"},{"key":"10.1016\/j.critrevonc.2026.105269_bib108","doi-asserted-by":"crossref","first-page":"782","DOI":"10.3724\/abbs.2024198","article-title":"SIRP\u03b1 modulates the podocyte cytoskeleton through influencing the phosphorylation of FAK at tyrosine residue 597","volume":"57","author":"Xia","year":"2025","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"10.1016\/j.critrevonc.2026.105269_bib109","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.immuni.2017.07.016","article-title":"Dendritic cells but not macrophages sense tumor mitochondrial DNA for cross-priming through signal regulatory protein \u03b1 signaling","volume":"47","author":"Xu","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.critrevonc.2026.105269_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114235","article-title":"Dual STING activation and CD47\/SIRP\u03b1 blockade via chitooligosaccharide-based nanoparticles to amplify antitumor immunity","volume":"387","author":"Xu","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.critrevonc.2026.105269_bib111","article-title":"Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy","volume":"14","author":"Xu","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105269_bib112","article-title":"Activation of RIG-I\/MDA5 Signaling and Inhibition of CD47-SIRP\u03b1 Checkpoint with a Dual siRNA-Assembled Nanoadjuvant for Robust Cancer Immunotherapy","volume":"63","author":"Xu","year":"2024","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.critrevonc.2026.105269_bib113","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/hep.20360","article-title":"Negative regulation of hepatocellular carcinoma cell growth by signal regulatory protein alpha1","volume":"40","author":"Yan","year":"2004","journal-title":"Hepatol. Baltim. Md"},{"key":"10.1016\/j.critrevonc.2026.105269_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e39858","article-title":"IMM2520, a novel anti-CD47\/PD-L1 bispecific antibody for cancer immune therapy","volume":"10","author":"Yang","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.critrevonc.2026.105269_bib115","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40364-023-00456-x","article-title":"The landscape overview of CD47-based immunotherapy for hematological malignancies","volume":"11","author":"Yang","year":"2023","journal-title":"Biomark. Res."},{"key":"10.1016\/j.critrevonc.2026.105269_bib116","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13045-024-01646-2","article-title":"Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRP\u03b1, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a phase 1\/2 study","volume":"17","author":"Yang","year":"2024","journal-title":"J. Hematol. Oncol. J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105269_bib117","article-title":"Expression of SIRP\u03b1-Fc by oncolytic virus enhances antitumor efficacy through tumor microenvironment reprogramming","volume":"16","author":"Yang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105269_bib118","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41392-024-01859-4","article-title":"Genetically programmable cell membrane-camouflaged nanoparticles for targeted combination therapy of colorectal cancer","volume":"9","author":"Yang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.critrevonc.2026.105269_bib119","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s12943-023-01885-w","article-title":"Exploiting innate immunity for cancer immunotherapy","volume":"22","author":"Yi","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105269_bib120","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/blood.2024027408","article-title":"Magrolimab plus azacitidine vs physician\u2019s choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study","volume":"146","author":"Zeidner","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105269_bib121","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1038\/ncomms3436","article-title":"Inflammation-induced proteolytic processing of the SIRP\u03b1 cytoplasmic ITIM in neutrophils propagates a proinflammatory state","volume":"4","author":"Zen","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105269_bib122","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12974-025-03414-6","article-title":"SIRP\u03b1 modulates microglial efferocytosis and neuroinflammation following experimental subarachnoid hemorrhage via the SHP1\/STAT6 axis","volume":"22","author":"Zhang","year":"2025","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.critrevonc.2026.105269_bib123","article-title":"Checkpoint Nano-PROTACs for Activatable Cancer Photo-Immunotherapy","volume":"35","author":"Zhang","year":"2023","journal-title":"Adv. Mater. Deerfield Beach Fla"},{"key":"10.1016\/j.critrevonc.2026.105269_bib124","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/s41423-024-01220-3","article-title":"Silencing of SIRP\u03b1 enhances the antitumor efficacy of CAR-M in solid tumors","volume":"21","author":"Zhang","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105269_bib125","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12943-023-01725-x","article-title":"Roles of tumor-associated macrophages in anti-PD-1\/PD-L1 immunotherapy for solid cancers","volume":"22","author":"Zhang","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105269_bib126","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12379","article-title":"Engineering high-affinity dual targeting cellular nanovesicles for optimised cancer immunotherapy","volume":"12","author":"Zhang","year":"2023","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.critrevonc.2026.105269_bib127","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12943-025-02305-x","article-title":"Advances in cancer immunotherapy: historical perspectives, current developments, and future directions","volume":"24","author":"Zhang","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105269_bib128","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fimmu.2020.00018","article-title":"Advances in Anti-Tumor Treatments Targeting the CD47\/SIRP\u03b1 Axis","volume":"11","author":"Zhang","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105269_bib129","article-title":"Targeted release of a bispecific fusion protein SIRP\u03b1\/Siglec-10 by oncolytic adenovirus reinvigorates tumor-associated macrophages to improve therapeutic outcomes in solid tumors","volume":"13","author":"Zhang","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105269_bib130","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jconrel.2021.11.028","article-title":"Nanomaterials targeting tumor associated macrophages for cancer immunotherapy","volume":"341","author":"Zhao","year":"2022","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"10.1016\/j.critrevonc.2026.105269_bib131","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.gendis.2022.12.008","article-title":"Targeting CD47-SIRP\u03b1 axis for Hodgkin and non-Hodgkin lymphoma immunotherapy","volume":"11","author":"Zhao","year":"2024","journal-title":"Genes Dis."},{"key":"10.1016\/j.critrevonc.2026.105269_bib132","article-title":"M2-Like TAMs function reversal contributes to breast cancer eradication by combination dual immune checkpoint blockade and photothermal therapy","volume":"17","author":"Zhao","year":"2021","journal-title":"Small Weinh. Bergstr. Ger."},{"key":"10.1016\/j.critrevonc.2026.105269_bib133","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.ccell.2022.10.012","article-title":"Tumor-intrinsic SIRPA promotes sensitivity to checkpoint inhibition immunotherapy in melanoma","volume":"40","author":"Zhou","year":"2022","journal-title":"Cancer Cell"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001563?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001563?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T06:39:00Z","timestamp":1778481540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826001563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":133,"alternative-id":["S1040842826001563"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105269","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The versatility of SIRP\u03b1: Novel perspectives on tumor microenvironment regulation and targeted therapy beyond the CD47-SIRP\u03b1 axis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105269","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105269"}}